Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules
- 21 May 2004
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (7) , 497-507
- https://doi.org/10.1038/sj.cgt.7700708
Abstract
One of the strategies to promote an antitumor response is the genetic modification of tumor cells to induce expression of costimulatory molecules. We have tested the capacity of a soluble form of CD70 molecule (sCD70). After construction of a vector carrying the sCD70, we obtained stable sCD70-secreting TS/A tumor cells and allogenic MC57 fibroblasts. In all, 45% of wild-type (wt) tumors were rejected in immunocompetent mice when transfected sCD70-secreting cells were injected three times in the periphery of the wt tumors. Furthermore, the sCD70-secreting TS/A cells induced a protective memory against wt TS/A tumor growth: 70% of the wt tumors used for the challenge were rejected by mice, which had rejected tumors 45 days before in the presence of sCD70-secreting TS/A cells. It was also shown that in vitro mock TS/A tumor cell proliferation was inhibited by splenocytes harvested from mice injected with TS/A cells expressing CD70. Growth kinetics of wt TS/A tumors in immunocompetent versus nude mice suggested that T lymphocytes were implicated in the antitumor response, which was confirmed by membrane expression of specific markers. The data suggest that injection of genetically transfected cells secreting sCD70 in the periphery of wt TS/A tumors induces T-cell-mediated inhibition of tumor growth and builds up a protective antitumor memory.Keywords
This publication has 27 references indexed in Scilit:
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cellsCancer Gene Therapy, 2002
- The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC statusCancer Gene Therapy, 2000
- Control of lymphocyte function through CD27–CD70 interactionsSeminars in Immunology, 1998
- Tumor necrosis factor receptor family members in the immune systemSeminars in Immunology, 1998
- Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cellsEuropean Journal of Immunology, 1998
- T-cell activation: integration of signals from the antigen receptor and costimulatory moleculesImmunology Today, 1995
- Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory responseEuropean Journal of Immunology, 1995
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990